239 related articles for article (PubMed ID: 34541001)
21. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.
Hermes-Lima M; Gonçalves MS; Andrade RG
Mol Cell Biochem; 2001 Dec; 228(1-2):73-82. PubMed ID: 11855743
[TBL] [Abstract][Full Text] [Related]
22. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation.
Maurício AQ; Lopes GK; Gomes CS; Oliveira RG; Alonso A; Hermes-Lima M
Biochim Biophys Acta; 2003 Mar; 1620(1-3):15-24. PubMed ID: 12595068
[TBL] [Abstract][Full Text] [Related]
23. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
Buss JL; Arduini E; Ponka P
Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
[TBL] [Abstract][Full Text] [Related]
24. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
25. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
Chen YL; Kong X; Xie Y; Hider RC
J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
[TBL] [Abstract][Full Text] [Related]
26. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe.
Huang AR; Ponka P
Biochim Biophys Acta; 1983 Jun; 757(3):306-15. PubMed ID: 6849979
[TBL] [Abstract][Full Text] [Related]
27. Pyridoxal isonicotinoyl hydrazone inhibition of FXR is involved in the pathogenesis of isoniazid-induced liver injury.
Zhang G; Chen L; Wen Y; Rao Z; Wei Y; Wu X
Toxicol Appl Pharmacol; 2020 Sep; 402():115134. PubMed ID: 32673658
[TBL] [Abstract][Full Text] [Related]
28. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
Ponka P; Schulman HM; Wilczynska A
Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of neuronal ferroptosis in the acute phase of intracerebral hemorrhage shows long-term cerebroprotective effects.
Chen B; Chen Z; Liu M; Gao X; Cheng Y; Wei Y; Wu Z; Cui D; Shang H
Brain Res Bull; 2019 Nov; 153():122-132. PubMed ID: 31442590
[TBL] [Abstract][Full Text] [Related]
30. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
Ponka P; Richardson DR; Edward JT; Chubb FL
Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
[TBL] [Abstract][Full Text] [Related]
31. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction.
Hermes-Lima M; Santos NC; Yan J; Andrews M; Schulman HM; Ponka P
Biochim Biophys Acta; 1999 Feb; 1426(3):475-82. PubMed ID: 10076064
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate.
Chitambar CR; Boon P; Wereley JP
Clin Cancer Res; 1996 Jun; 2(6):1009-15. PubMed ID: 9816262
[TBL] [Abstract][Full Text] [Related]
33. CDGSH iron sulfur domain 2 over-expression alleviates neuronal ferroptosis and brain injury by inhibiting lipid peroxidation via AKT/mTOR pathway following intracerebral hemorrhage in mice.
Li R; Zhang X; Gu L; Yuan Y; Luo X; Shen W; Xie Z
J Neurochem; 2023 May; 165(3):426-444. PubMed ID: 36802066
[TBL] [Abstract][Full Text] [Related]
34. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
35. Salvianolic acid A inhibits ferroptosis and protects against intracerebral hemorrhage.
Shi Y; Yan D; Nan C; Sun Z; Zhuo Y; Huo H; Jin Q; Yan H; Zhao Z
Sci Rep; 2024 May; 14(1):12427. PubMed ID: 38816543
[TBL] [Abstract][Full Text] [Related]
36. Aging-related changes in the iron status of skeletal muscle.
DeRuisseau KC; Park YM; DeRuisseau LR; Cowley PM; Fazen CH; Doyle RP
Exp Gerontol; 2013 Nov; 48(11):1294-302. PubMed ID: 23994517
[TBL] [Abstract][Full Text] [Related]
37. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
Vitolo ML; Clare BW; Hefter GT; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
[No Abstract] [Full Text] [Related]
38. Effect of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture.
Richardson D; Baker E; Ponka P; Wilairat P; Vitolo ML; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):81-8. PubMed ID: 3390577
[No Abstract] [Full Text] [Related]
39. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
40. Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator.
Brock JH; Stevenson J
Immunol Lett; 1987 May; 15(1):23-5. PubMed ID: 3610230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
